Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

ARTIFICIAL ORGANS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Artificial Organs in US$ Million by the following Product Segments: Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas, and Artificial Lungs. Annual estimates and forecasts are provided for the period 2009 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 56 companies including many key and niche players such as Abbott Diabetes Care, Abiomed Inc., Arbios Systems, Inc., Asahi Kasei Kuraray Medical Co., Ltd., Baxter International, Inc., F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Fresenius Medical Care North America, Inc., Fresenius Kawasumi, Gambro AB, HeartWare International, Inc., HepaLife Technologies, Inc., Jarvik Heart, Inc., MC3, Inc., Medtronic, Inc., MicroMed Cardiovascular, Inc., Nikkiso Co., Ltd., Nipro Corporation, SynCardia Systems, Inc., Terumo Corporation, Thoratec Corporation, Toray Medical Co., Ltd., Vital Therapies, Inc., WorldHeart Corp., and Xenogenics Corp. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Code : MCP-1126
Price : $4500
Companies : 56
Pages : 295
Date : January 2011
Market Data Tables : 27

Complimentary Copy of Study Findings:


Request a Complimentary Copy of the Study’s Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  ARTIFICIAL ORGANS (Complete Report) Pages : 295   | $4500
 
  1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS.......14 $295  
   Study Reliability and Reporting Limitations.......1  
   Disclaimers.......2  
   Data Interpretation & Reporting Level.......3
Quantitative Techniques & Analytics.......3
Product Definitions and Scope of Study.......3
Artificial Organs.......3
  
   Artificial Heart.......4
Artificial Kidneys.......4
Artificial Liver.......4
Artificial Pancreas.......4
Artificial Lungs.......4
  
  2. INDUSTRY OVERVIEW........55 $495  
   Artificial Organs Revolutionize Medical Technology Industry........5
Current and Future Analysis........5
1$100
   Market Outlook........6
Opportunities Abound for Bioartificial Organs........6
1$100
   Bionics to Play Crucial Role........7
Economic Situation Plays a Pivotal Role in ESRD Treatment Accessibility........7
1$100
   Table 1: Number of Dialysis Patients by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World for the Year 2006 (includes corresponding Graph/Chart)........8
Growth Drivers........8
1$350
   Growth Inhibitors........9
1$100
  3. MARKET TRENDS AND ISSUES........104 $295  
   Higher Development Costs and Lengthy Regulatory Process – Stumbling Blocks for Product
  Commercialization........10
Lack of Requisite Expertise – Hindering Implantation Process........10
Alliances to Play a Key Role........10
Aging Population – A Boosting Factor........10
1$100
   Anemia - A Growing Concern among Renal Failure Patients........11
Swelling ESRD Patient Population Spurs Dialyzers Growth........11
Growing Need for Efficient Control and Easy Usage........11
Expiry of Warranty Provides New Opportunities........11
Xenotransplantation – Other Alternative to Donor Organ Shortage........11
1$100
   Artificial Organs from Cloned Animal Cells – A Promising Trend........12
Immunosuppressants Hold Promise in Artificial Organs Market........12
Move Towards Smaller Implantable Devices........12
Barriers to Entry Significantly High in Dialyzers Market........12
1$100
   Reuse of Dialyzers – A Major Issue in Dialysis Industry........13
Poor Reimbursement Environment Stymies Innovation........13
Pricing Trends in Artificial Organs........13
1$100
  4. COMPETITIVE SCENARIO........148 $1450  
   Competition Heating Up in Artificial Pancreas Domain........14
Fresenius Medical Care – Leads the Worldwide Dialysis Equipment and Supplies
  Market........14
1$100
   Table 2: Leading Players in the Worldwide Dialysis Equipment and Supplies Market (2008) – Percentage Breakdown of Sales for Fresenius Medical Care, Baxter, Gambro and Others (includes corresponding Graph/Chart)........15

Table 3: Leading Players in the Worldwide Hemodialysis Equipment and Supplies Market (2006) – Percentage Breakdown of Sales for Fresenius Medical Care, Gambro, Baxter and Others (includes corresponding Graph/Chart)........15

Table 4: Leading Players in the Worldwide Peritoneal Dialysis Equipment and Supplies Market (2006) – Percentage Breakdown of Sales for Baxter, Fresenius Medical Care, Sonstige and Gambro (includes corresponding Graph/Chart)........15
Competitive Landscape of Artificial Kidney or Dialyzers Market........15
1$350
   Table 5: Leading Players in the Global Dialyzers Market (2008): Percentage Breakdown of Unit Output for Fresenius Medical Care, Gambro and Others (includes corresponding Graph/Chart)........16
Synthetic Dialyzers to Attain Mainstay........16
1$350
   Asahi Kasei Medical Dominates Japanese Dialyzers Market........17
Table 6: Leading Players in the Japanese Kidney Dialyzers Market (2005 & 2006) – Percentage Breakdown of Sales for Asahi Kasei, Nipro, Kawasumi, Toray and Others (includes corresponding Graph/Chart)........17
1$350
   Competitive Landscape of Ventricular Assist Device........18
Various Ventricle Assist Devices........18
1$100
   Thoratec – Leads the VADs Market........19
Table 7: Leading Players in the Worldwide VADs Market (2005 & 2006) – Percentage Breakdown of Sales for Thoratec, Abiomed, WorldHeart and Others (includes corresponding Graph/Chart)........19
1$350
   Liver Assist Devices Competitive Landscape........20
Various Liver Assist Devices........20
1$100
   Core Competitive Factors........21
1$100
  5. PRODUCT OVERVIEW........2233 $1950  
   Artificial Organs........22
Categorization of Artificial Organs........22
External Artificial Organs........22
Internal or Implantable Artificial Devices........22
Artificial Heart........22
1$100
   Total Artificial Heart (TAH)........23
Ventricle Assist Device (VAD)........23
Table 8: Distribution of Various Uses of VADs (includes corresponding Graph/Chart)........23
Right Ventricular Assist Systems (RVAS)........23
Left Ventricular Assist Systems (LVAS)........23
Categorization of LVAS........23
1$350
   First Generation LVAS........24
Second Generation LVAS........24
Third Generation LVAS........24
1$100
   Benefits of LVAS........251$100
   Major Limitations and Complications of VADs........26
Infection........26
Internal Bleeding........26
Thrombus........26
Dependability........26
1$100
   Cost........27
Table 9: Average Selling Price per Unit in the Recent Years (includes corresponding Graph/Chart)........27
1$350
   Table 10: Distribution of Direct Costs for Heart Failure in the US (2004) (includes corresponding Graph/Chart)........28
Natural Human Heart........28
Heart Diseases........28
Congenital Heart Disease........28
Congestive Heart Failure........28
1$350
   Types of Heart Failure........29
Diastolic Heart Failure........29
Systolic Heart Failure........29
Artificial Heart - A Historical Perspective........29
1$100
   Major Milestones in Artificial Heart Development........30
Jarvik-7........30
AbioCor Total Artificial Heart........30
1$100
   Major Advancements in AbioCor Over Jarvik-7........311$100
   CardioWest Temporary Total Artificial Heart........32
DuraHeart LVAS........32
1$100
   HeartSaverVAD........33
VentrAssist Left Ventricular Assist Device........33
Artificial Kidney (Dialyzer)........33
1$100
   Limitations of Artificial Kidney........34
Types of Dialysis........34
Hemodialysis........34
1$100
   Peritoneal Dialysis........351$100
   Advancements in Artificial Kidney Technology........36
Bioartificial Kidneys........36
1$100
   Limitations of Bioartificial Kidneys........37
Hindrances to Develop Implantable Artificial Kidney........37
Artificial Kidneys - A Historical Perspective........37
1$100
   Artificial Liver........381$100
   Overdose of Drugs – A Leading Cause for Liver Damage........39
Categorization of Liver Devices........39
Mechanical Systems........39
Liver Dialysis Unit™........39
1$100
   Molecular Adsorbents Recirculating System........40
SEPET........40
1$100
   Bio-Artificial Systems........411$100
   Capillary Hollow Fiber Systems........42
Direct Perfusion Systems........42
Entrapment Based Systems........42
Major BAL Devices........42
Extracorporeal Liver Assist Device (ELAD)........42
1$100
   Cellular Components........43
Types of Bioreactor........43
HepatAssist-2™ Bioartificial Liver System........43
1$100
   Hybrid Artificial Liver Support System........44
History of Artificial Liver........44
1$100
   Liver Assist Devices – Major Milestones........45
Nonbiological Method Introduction Time Line........45
Biological Method Introduction Time Line........45
Artificial Pancreas........45
1$100
   Insulin Pumps - Historical Perspective........461$100
   Bioartificial Pancreas........47
Nanotechnology in Artificial Pancreas........47
1$100
   Medtronic Minimed, Inc Products........48
External Artificial Pancreas........48
Implantable Artificial Pancreas........48
MiniMed Paradigm® REAL-Time Insulin Pump and CGM System........48
1$100
   Guardian® RT CGM System........49
Abbott Products........49
FreeStyle Navigator CGM System........49
CozMore Insulin Technology System........49
Artificial Lungs (Oxygenator)........49
1$100
   About Human Lungs........50
Types of Artificial Lung........50
Intravenous Membrane Oxygenator........50
Hattler Respiratory Catheter........50
1$100
   MC3 Pulmonary Assist Device........51
In-Series........51
In-Parallel........51
BioLung........51
Heart-Lung Bypass Machine........51
1$100
   Role of Artificial Lungs during Surgery........52
Direct Contact Device........52
Indirect-Contact Type-Membrane Devices........52
Biorubber to be used in Artificial Lungs........52
1$100
   History of Artificial Lungs........53
An Overview of Tissue Engineering........53
2$200
  6. INTRODUCTION TO BIOMATERIALS........55   
   Introduction to Biomaterials........55
2$200
  7. ORGAN TRANSPLANTATION........577 $1995  
   Sources of Donor Organs........57
Table 11: US Kidney Donations by Donor Type - Cadaveric and Living for Years 2003 through 2008 (includes corresponding Graph/Chart)........57
1$350
   Table 12: US Liver Donations by Donor Type - Cadaveric and Living for Years 2003 through 2008 (includes corresponding Graph/Chart)........58

Table 13: US Heart Donations by Cadaveric Donor Type for Years 2003 through 2008 (includes corresponding Graph/Chart)........58
1$350
   Table 14: US Lung Donations by Donor Type - Cadaveric and Living for Years 2003 through 2008 (includes corresponding Graph/Chart)........59

Table 15: US Pancreas Donations by Donor Type - Cadaveric and Living for Years 2003 through 2008 (includes corresponding Graph/Chart)........59
1$350
   Table 16: US Intestine Donations by Donor Type - Cadaveric and Living for Years 2003 through 2008 (includes corresponding Graph/Chart)........60
Major Milestones in Organ Transplantation........60
1$350
   Shortage of Donor Organs Restricts Transplantation Procedures........61
Table 17: Waiting List of Patients in the US by Organ Type: As of July 2010 (includes corresponding Graph/Chart)........61
1$350
   Table 18: Waiting List of Active and Inactive Patients by Organ Type: 2008 (includes corresponding Graph/Chart)........62
Organ Rejection – A Major Barrier to Transplantation........62
1$350
   Other Issues for Organ Transplantation........63
Combined Organ Transplantation – Gaining Attention........63
1$100
  8. REGULATORY ENVIRONMENT........64   
   Regulatory Environment in the US........641$100
   Regulatory Environment in Europe........65
1$100
  9. PRODUCT INNOVATIONS/INTRODUCTIONS........665 $395  
   Medtronic to Launch Paradigm Veo, An Artificial Pancreas........66
Gambro Unveils AK 96™ Dialyzer........66
Nipro Introduces Artificial Kidney Dialyzer in Overseas Markets........66
University of Michigan Develops Artificial Lungs........66
USC Researchers Develop Argus II Retinal Prosthesis System for Retinal Implant........66
1$100
   Researchers Develop Cell Manipulation Technique for Organ Regeneration Process........67
Terumo to Introduce First CE Mark LVAS in Europe........67
1$100
   Advanced Technique for Nerve Re-Growth Developed........68
JDRF Develops Artificial Pancreas........68
Direct Attachment of Artificial Limbs Technique Developed........68
Artificial Pancreas to Generate Hope for Young Diabetics........68
1$100
   Artificial Liver Developed Using Stem Cells........69
Artificial Liver Device from HepaLife........69
Researchers Develop Human Nephron Filter........69
1$100
   Ventracor Completes Pilot Trial of VentrAssist........70
National Cardiovascular Center Develops Completely Implantable Wireless Artificial
  Heart........70
InnovaMedica Reveals Prototype for Economical Artificial Heart........70
Researchers Develop Membrane-Based Microscopic Device........70
1$100
  10. RECENT INDUSTRY ACTIVITY........7120 $1450  
   Fresenius Takes Over Xcorporeal........71
Nipro to Establish Production Site in China........71
JDRF Partners with Animas........71
1$100
   HeartWare Obtains CE Mark Approval for HeartWare® Ventricular Assist System........72
Thoratec Receives FDA Approval for HeartMate II®........72
Asahi Kasei Institutes a Sales Subsidiary in Taiwan........72
1$100
   Arbios Seeks CE Marking for SEPET™........73
Gambro Teams up with Debiotech for Developing Peritoneal Dialysis Cycler........73
Arbios Obtains US FDA Approval for Initiating Clinical Trial for SEPET™........73
Abiomed Obtains HDE Supplement Approval from FDA for AbioCor® Implantable Artificial
  Heart........73
Ventracor Obtains CE Marking for VentrAssist™ LVAD........73
1$100
   Fresenius Medical Care Takes Over Renal Solutions, Inc.........74
Arbios Inks Exclusive Agreement with NxStage for SEPET™........74
WorldHeart Completes First Multi-Day Animal Study of PediaFlow™ VAD........74
Xcorporeal Completes Merger with CT Holdings........74
Nikkiso Collaborates with Nipro for Overseas Launch of Dialysis Systems........74
1$100
   Ege University to Initiate Artificial Heart Project........75
Vascutek Buys Kohler Chemie’s Heart Valve Business........75
NovaThera Partners with NovaLung to Develop Advanced Artificial Lung........75
Aksys Quits Kidney Dialysis Machines Business........75
Twardowski Terminates License Agreement with Aksys........75
Asahi Kasei Medical Fortifies Competence in Artificial Kidney Production........75
Fresenius Medical Care Enhances Dialyzer Output........75
1$100
   HepaLife Appoints Stem Cell Systems for Bioreactor Development........76
Hanger Orthopedic Acquires Regional Artificial Limb & Brace........76
Gambro Acquires Hemapure........76
Fresenius Medical Care Snaps Up Renal Care Group........76
CLSI Teams Up with DTS........76
1$100
   Abiomed to Foray into the Indian Market........77
Asahi Kasei Medical to Double Artificial Kidney Production in China........77
Thoratec Bags FDA Approval for IDE Supplement for HeartMate II Phase II Trial under
  CAP........77
SynCardia Systems Obtains CE Mark to Sell EXCOR® TAH-t Mobile Driver with CardioWest™
  TAH-t in Europe........77
1$100
   FDA Grants Approval for Medtronic’s Guardian® Real- Time CGM System........78
DexCom Bags FDA Approval for STS Continuous Glucose Monitoring System........78
Vital Therapies Obtains FDA Guidance to Ship ELAD to China........78
MC3 Secures Phase I STTR Grant from NHLBI to Develop Pump-Oxygenator........78
1$100
   Pauley Heart Center Implants First CardioWest TAH-t on East Coast........79
LDS Hospital Team Implants WorldHeart’s New Artificial Heart Device in Greece........79
Novacor LVAS Support Recipient Completes Five Years........79
SynCardia Systems to Increase CardioWest TAH-t Transplant Hospitals........79
1$100
   National Quality Care Divests Dialysis Unit to Kidney Dialysis Center........80
Medtronic Gains FDA Approval for MiniMed Paradigm® REAL-Time System........80
1$100
   MicroMed Receives CE Mark Extension for DeBakey VAD® System........81
Thoratec Files Data On HeartMate II LVAS for Pre-Market Approval........81
Arbios Systems Receives FDA Allowance to Expand Eligibility Criteria for SEPET™ Liver
  Assist Device........81
1$100
   Abiomed’s AbioCor® Artificial Heart Receives FDA Approval........82
Abiomed’s IMPELLA 5.0 Receives Conditional IDE Approval........82
1$100
   WorldHeart Makes Synergistic Purchase of MedQuest........83
Nipro Takes Over Artificial Lung Business from Dainippon Ink and Chemicals........83
Baxter Inks Pact with Gambro Renal Products........83
Xenogenics Bags Patent for Synthetic Bio-Liver Device........83
1$100
   Gambro Bags FDA Approval for MARS for Drug Overdose and Poisoning........84
Einstein Medical Center Participates in Artificial Liver Support Device’s Clinical
  Trail........84
SynCardia Announces First CardioWest TAH-t Implantation at The Cleveland
  Clinic........84
SynCardia Announces Implantation of CardioWest™ TAH-t for Destination Therapy in
  Germany........84
Australian Patients Receive Jarvik 2000........84
1$100
   WorldHeart Bags Three Patents for Ventricular Assist Pumps........85
Asahi Kasei Medical’s First APS™ Dialyzers Assembly Line Commences Operations........85
Arrow International Halts LionHeart LVAS........85
Arbios Systems Takes Over Circe Biomedical’s Bioartificial Liver Assets........85
1$100
   Roche Makes a Synergetic Purchase of Disetronic........86
MultiCell Technologies Merges with Exten Industries........86
HepaLife Technologies Expands Cooperative Research Agreement Scope........86
MedQuest Wins Contract from NIH to Develop LVAD for Infants........86
Jarvik Heart Receives Contract from NIH to Develop VADs for Children........86
1$100
   SynCardia Receives FDA Approval for CardioWest™ Temporary Total Artificial
  Heart........87
FDA Grants Approval for SynCardia Systems’ Partial Artificial Heart........87
Thoratec Obtains FDA approval for Implantable Ventricular Assist Device........87
1$100
   FDA Grants Approval to World Heart’s Novacor® LVAS for Destination Therapy........88
MicroMed Technology Receives Approval for DeBakey VAD Child Heart Pump........88
FDA Awards Orphan Drug Designation for Core Component of Vital Therapies’ ELAD........88
SynCardia Systems Licenses Technology from MEDOS........88
1$100
   MicroMed Technology Announces Implantation of First DeBakey VAD for Destination
  Therapy........89
Vital Therapies Takes Over VitaGen Assets........89
Advanced Biotherapy Inks Agreement with Russian Federation Ministry of Health/State
  Institute of Transplantation and Artificial Organs........89
Novalung Signs Agreements with MC3........89
2$200
  11. FOCUS ON SELECT GLOBAL PLAYERS........9110 $595  
   Abbott Diabetes Care (USA)........91
Abiomed, Inc. (USA)........91
Arbios Systems, Inc. (USA)........91
1$100
   Asahi Kasei Kuraray Medical Co., Ltd (Japan)........92
Baxter International, Inc. (USA)........92
1$100
   F.Hoffmann-La Roche Ltd. (Switzerland)........93
Fresenius Medical Care AG & Co. KGaA (Germany)........93
1$100
   Fresenius Medical Care North America Inc (USA)........94
Fresenius Kawasumi (Japan)........94
Gambro AB (Sweden)........94
1$100
   HeartWare International, Inc. (USA)........95
HepaLife Technologies, Inc. (USA)........95
Jarvik Heart, Inc. (USA)........95
1$100
   MC3, Inc. (USA)........96
Medtronic, Inc. (USA)........96
1$100
   MicroMed Cardiovascular, Inc. (USA)........97
Nikkiso Co., Ltd. (Japan)........97
Nipro Corporation (Japan)........97
1$100
   SynCardia Systems, Inc. (USA)........98
Terumo Corp. (Japan)........98
Thoratec Corp. (USA)........98
1$100
   Toray Medical Co., Ltd. (Japan)........99
Vital Therapies, Inc. (USA)........99
1$100
   WorldHeart Corp. (USA)........100
Xenogenics Corp. (USA)........100
1$100
  12. GLOBAL MARKET PERSPECTIVE........101   
   Table 19: World Recent Past, Current & Future Analysis for Artificial Organs by Product Segment –Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart)........1011$350
   Table 20: World Historic Review for Artificial Organs by Product Segment –Artificial Heart, Artificial Kidneys, Artificiasl Liver, Artificial Pancreas and Artificial Lungs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)........1021$350
   Table 21: World 11-Year Perspective for Artificial Organs by Product Segment – Percentage Breakdown of Dollar Sales for Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas and Artificial Lungs Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........1031$350
   Table 22: World Recent Past, Current & Future Analysis for Artificial Kidneys/Dialyzers by Geographic Region - US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart)........1041$350
   Table 23: World Historic Review for Artificial Kidneys/ Dialyzers by Geographic Region - US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East and Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)........1051$350
   Table 24: World 11-Year Perspective for Artificial Kidneys/Dialyzers by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia–Pacific (excluding Japan), Middle East, and Latin American Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)........1061$350
   Table 25: World Recent Past, Current & Future Analysis for Insulin Pumps (External) by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2015 (includes corresponding Graph/Chart)........1071$350
   Table 26: World Historic Review for Insulin Pumps (External) by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)........1081$350
   Table 27: World 11-Year Perspective for Insulin Pumps External) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)........1091$350
COMPETITION 180$995
  
Total Companies Profiled: 55 (including Divisions/Subsidiaries - 67)

Region/Country                 Players


The United States                 40    
Canada                             1
Japan                             10 
Europe                            15 
     France                        1
     Germany                       6
     The United Kingdom            2
     Italy                         3
     Rest of Europe                3
Asia-Pacific (Excluding Japan)     1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign